Takeda reports Phase 3 results showing skin clearance with TAK-279 in plaque psoriasis

Takeda presented Phase 3 data at the 2026 AAD meeting showing once-daily oral TAK-279 (zasocitinib) produced rapid, durable skin clearance in adults with moderate-to-severe plaque psoriasis, with about 69–71% achieving sPGA 0/1 at week 16 and responses increasing through week 24.

Takeda presented new results from two pivotal Phase 3 studies of zasocitinib (TAK-279) at the 2026 American Academy of Dermatology Annual Meeting. The trials enrolled adults with moderate-to-severe plaque psoriasis and evaluated a once-daily oral tyrosine kinase 2 inhibitor. The studies were randomized, multicenter and double-blind, and included both placebo and an active comparator. Reported findings focus on skin clearance at week 16 and response durability through week 24. Key findings: - Trials: Latitude PsO 3001 and 3002 were randomized, multicenter, double-blind, placebo- and active comparator-controlled. - sPGA 0/1 at week 16: 71.4% and 69.2% of patients treated with zasocitinib achieved clear or almost clear skin versus placebo and apremilast. - PASI 90 at week 16: 61.3% and 51.9% of patients treated with zasocitinib achieved Psoriasis Area and Severity Index 90 versus placebo and apremilast. - Complete skin clearance (sPGA 0) at week 16: 39.9% and 33.7% of patients treated with zasocitinib achieved sPGA 0 versus placebo and apremilast. - PASI 100 at week 16: 33.4% and 25.2% of patients treated with zasocitinib achieved complete clearance versus placebo and apremilast. - Safety: The safety profile was reported as consistent with Phase 2b studies, and responses for co-primary and key secondary endpoints continued to increase through week 24. Summary: These Phase 3 results indicate that once-daily oral zasocitinib produced rapid and durable skin clearance in the studied population, with multiple efficacy endpoints showing higher response rates at week 16 and continued improvement by week 24. The safety profile was reported as consistent with earlier studies. Undetermined at this time.